Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
MYGN Stock — Myriad Genetics Inc
Myriad Genetics Inc (MYGN)
Updated October 16, 2026.
MYGN is a Stock. Total return is -14.2% over the past 31 years, 2145.9 points behind SPY at 2131.7%.
Myriad Genetics is a molecular diagnostics and precision medicine company that develops and offers DNA sequencing tests and molecular diagnostic tests for oncology, women's health, pharmacogenomics, and prenatal screening, along with tumor profiling tests to assess cancer aggressiveness and treatment response. The company does not currently distribute dividends to shareholders. Myriad appeals to investors seeking exposure to the precision medicine and diagnostics sector rather than those focused on dividend income.
MYGN dividend yield and income
Price as of 2026-10-16.
The ex-dividend date is 07/01/2009.
| Ex-date | Amount | Change from previous payment |
|---|---|---|
| 2009-07-01 | $1.75 | 0.0% Unclassified cash |
| 2009-06-15 | $1.75 | — |
| 2009 total | $3.5 | — |
MYGN performance versus SPY
Price and return data through 2026-10-16.
Total return is -14.2% over the past 31 years, 2145.9 points behind SPY at 2131.7%. Over the past year its total return — price change plus distributions reinvested — is -50.7%. Its deepest 1-year drawdown was 65.0%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | 3.1% | — |
| 3M | -35.7% | — |
| 6M | -20.4% | — |
| YTD | -35.3% | — |
| 1Y | -50.7% | — |
| 2Y CAGR | — | -59.20% |
| 3Y CAGR | — | -35.60% |
| 5Y CAGR | — | -34.00% |
| 10Y CAGR | — | -14.30% |
| Since inception (31 years) | -14.2% | -0.50% |
MYGN key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 10/06/1995
- Distribution frequency
- None
- Last close
- $3.98 (as of 2026-10-16)
- Market cap
- $380,685,587
- Average volume
- 1425500.0
- Ex-dividend date
- 07/01/2009
- Beta
- 1.643
- Payout ratio
- 0.0%
- Forward P/E
- 54.0541
- EPS
- $-1.21
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
MYGN risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 65.0%.
Who may consider MYGN — and who may not
It is a weaker fit for investors who need monthly cash flow (MYGN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on MYGN
Frequently asked questions
Does MYGN pay monthly?
No. MYGN does not currently distribute.
When does MYGN pay a dividend?
MYGN does not currently distribute. The ex-dividend date is 07/01/2009.
How has MYGN performed?
Total return is -14.2% over the past 31 years, 2145.9 points behind SPY at 2131.7%. Over the past year its total return — price change plus distributions reinvested — is -50.7%. Its deepest 1-year drawdown was 65.0%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.